美国FDA批准斯丹赛生物基于通用CoupledCAR® 技术平台的首个候选产品GCC19CART 用于治疗复发或难治转移性结直肠癌的I期临床试验

ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) — 斯丹赛生物技术有限公司,作为一家多个产品管线已处在临床阶段的生物技术公司,自主研发了CoupledCAR®技术平台以治疗实体瘤,公司今日宣布美国FDA已经为公司的GCC19CART的新药临床试验申报授予了临床试验许可,以治疗复发或难治(R/R)转移性结直肠癌。斯丹赛生物预计将在2022年上半年在美国启动这项代号为CARAPIA-1的I期临床研究。

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

Loading...

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Loading...
Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.